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Background: We performed this study to determine the outcomes (pathologic
response, survival, local-regional control, and toxicity) in patients treated with
neoadjuvant chemoradiotherapy and planned operation for stage IIIA non–small cell
lung carcinoma.
Methods: Patients treated from 1993 to 2000 with neoadjuvant chemoradiotherapy
and a predetermined plan for subsequent surgical resection for stage III non–small
cell lung carcinoma were analyzed. All patients underwent pretreatment evaluation
at the university’s Multidisciplinary Lung Cancer Center. Most patients (87%) had
complete mediastinoscopy staging, and all were believed to be poor candidates for
up-front operation because of bulky extent of disease. The radiotherapy program
used conventional, 2-dimensionally planned treatment to 45 to 54 Gy in 1.8- to 2-Gy
fraction size. Concurrent chemotherapy consisted of etoposide/cisplatin or carbo-
platin/paclitaxel. Study end points included resectability, pathologic response, local-
regional control, survival, and toxicity. An exploratory comparison between patho-
logic response and long-term survival was performed. An exploratory comparison
between older chemotherapy (etoposide/cisplatin) and third-generation chemother-
apy (carboplatin/paclitaxel) was also performed.
Results: Of 53 patients, 45 (85%) were deemed surgical candidates after induction
therapy. Twenty-two (42% of the initial cohort) patients had a major pathologic
response to stage 0, I, or II disease. The 5-year actuarial survival was 31%. Major
pathologic response was associated with improved survival (48% vs 24%; P 
.027). The overall rate of early death potentially related to therapy in this series was
9%; this mostly occurred in patients who underwent right pneumonectomy. There
was no difference in efficacy or mortality between etoposide/cisplatin and radio-
therapy versus carboplatin/paclitaxel and radiotherapy, although the latter regimen
was associated with less grade 3 or higher acute toxicity necessitating interruption
or hospitalization during neoadjuvant treatment (P .02). In-field local control was
achieved in 83% of all patients (90% of the patients who underwent resection).
Brain metastases as the first site of treatment failure occurred in 23% of all patients.
Conclusions: Neoadjuvant concurrent chemoradiation delivers high resectability,
major pathologic response rate, and excellent local-regional control, with encour-
aging long-term survival considering the patient population studied. Major patho-
logic response correlates with long-term survival. Neoadjuvant carboplatin/pacli-
taxel and radiotherapy is an appropriate framework on which to add new therapies.
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Clinical stage IIIA non–small cell lung car-cinoma (NSCLC) is a major subgroup oflocally advanced NSCLC. It is now thestandard of care in the United States toincorporate systemic chemotherapy intothe treatment of this disease.1,2 It is gener-
ally accepted that chemotherapy should be combined with
local therapy consisting of radiotherapy (XRT), operation,
or both. The Intergroup (INT) mechanism, led by the Ra-
diation Therapy Oncology Group (RTOG), required 8 years
to complete a large clinical trial (INT protocol 0139) com-
paring chemoradiation with or without operation—a diffi-
cult randomization for physicians and patients to accept.3
Preliminary results have just become available.4 In the
meantime, institutions have performed smaller studies with
a variety of forms of induction, or preoperative, therapy for
clinical stage IIIA NSCLC.5-7
In the past decade, our institution has conducted a Multi-
disciplinary Lung Cancer Center, in which patients with com-
plex thoracic oncologic problems are simultaneously evaluated
by thoracic surgical, medical, and radiation oncologists. On the
basis of a prospectively designed Center policy, our group has
offered selected stage III NSCLC patients induction therapy
before definitive operation. Those patients with clinically ap-
parent N2 disease or other features that raised doubts about
complete resectability were offered neoadjuvant chemoradio-
therapy. We present the short-term and long-term outcomes
(pathologic response, toxicity, local-regional control [LRC],
and survival) from this clinical strategy.
Patients and Methods
This study analyzes the results of treatment at the University of
Pennsylvania for clinical stage III NSCLC in which definitive
operation was prospectively considered part of the treatment pro-
gram. The time period extends from 1993 to 2000. Before 1993,
patients with clinical stage III NSCLC were generally treated with
radical XRT with or without chemotherapy (no operation). All
patients in this series had good performance status (Zubrod scale
0-1) and no evidence of metastatic disease by computed tomo-
graphic (CT) scan of the chest/upper abdomen, bone scan, and
head CT or magnetic resonance imaging. All patients underwent
pulmonary function testing (at minimum, spirometry) before any
treatment and were believed to have adequate pulmonary reserve
to tolerate resection after neoadjuvant treatment.
All patients in this study were evaluated at the University of
Pennsylvania Multidisciplinary Lung Cancer Center. Physician
participants there include thoracic oncologic surgeons, medical
oncologists, radiation oncologists, diagnostic radiologists, pathol-
ogists, and pulmonologists. In this series, all patients had locally
advanced disease (stage III) that was judged to be marginally
resectable on the basis of CT scan findings. Positive N2 nodes were
those 1.5 cm or more in cross-sectional diameter. Histopathologic
documentation of N2 disease by mediastinoscopy or other invasive
procedure was strongly encouraged and was performed in 46 patients
(87% of the patients in this series). However, some patients (n  7)
were offered neoadjuvant therapy solely on the basis of unequivocal
imaging evidence of large N2 (4 cm) nodes or clinical stage (by CT
scan) T3-4 N1-2 disease because it was considered medically inap-
propriate to delay their treatment by several weeks to perform and
allow healing from mediastinoscopy. Patients with N3 disease as
determined by supraclavicular biopsy, CT scan, or mediastinoscopy
were not offered this treatment program. Patients with T4 disease, as
proven by thoracotomy, were also not offered this treatment, but
selected patients with evidence of T4 disease by CT scan were
included. To allow for a quality-assurance review of treatment deliv-
ery, for this study, only patients who had all of their treatment
(chemotherapy, radiation therapy, and operation) at the University of
Pennsylvania Medical Center were included.
Treatment Regimens
Briefly, the treatment program was as follows.
Radiotherapy. Radiation fields encompassed the primary tu-
mor, ipsilateral hilum, and bilateral mediastinal nodal regions
(minimum levels 2-7) to a dose of 45 to 54 Gy, limiting the spinal
cord dose to a maximum of 45 Gy. Conventional 2-dimensional
radiation planning was used, although computerized dosimetry
was performed in all cases. Target volume definition was based on
diagnostic and/or radiation treatment planning CT scans.
Chemotherapy. From 1993 to 1996, treatment consisted of
neoadjuvant XRT with concurrent cisplatin/etoposide (EP). Sys-
temic therapy consisted of 2 cycles of cisplatin (60-100 mg/m2)
and etoposide (120 mg/m2 for 3 days) given during the first and
fourth weeks of XRT, similar to the INT trial and the Southwest
Oncology Group phase II multicenter study designs.8 Starting in
1997, the preferred chemotherapy regimen was gradually changed
to concurrent carboplatin and paclitaxel on the basis of encourag-
ing data presented in unresectable stage III NSCLC9 and the
relative ease of outpatient administration with these drugs. Most of
these more recent patients received weekly paclitaxel (45-50 mg/
m2) and a dose of carboplatin based on an area under the curve
(AUC) formula (AUC  2). Because of travel/logistic issues,
several patients received 2 cycles of paclitaxel (135 mg/m2) and
carboplatin (AUC  5) during the first and fourth weeks of XRT.
All patients underwent noninvasive re-staging (CT scans of the
chest and head and bone scan) after induction therapy. Patients
who maintained a high performance status and had no evidence of
progressive disease underwent thoracotomy and attempted resec-
tion. Operation consisted of lobectomy (or pneumonectomy if
necessary) with complete mediastinal lymph node dissection, as
described by Mountain.10 In some cases, intercostal muscle flaps
were used as additional protection for the bronchial stump; how-
ever, this was not routinely performed in all cases. There was no
set institutional policy on postoperative or adjuvant therapy after
surgery; only a few patients were given adjuvant chemotherapy or
XRT after complete surgical resection. Details regarding adjuvant
chemotherapy for these few patients and data on salvage chemo-
therapy for patients who experienced recurrence are, unfortu-
nately, not available for this analysis.
Outcome Analysis
End points for this study included the following:
1. Resectability: proportion of patients who were able to un-
dergo resection of tumor with no gross residual disease (R0
or R1 procedure).
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2. Major pathologic response: proportion of patients who were
resectable with negative margins, had marked histopatho-
logic findings of tumor response, and were successfully
downstaged to pathologic stage 0, I, or II (T1-2 N0-1)
disease.
3. LRC: freedom from clinically progressive intrathoracic or
supraclavicular nodal disease, documented by biopsy where
appropriate.
4. Overall survival: survival calculated from the date of diag-
nosis.
5. Severe toxicity: National Cancer Institute common toxicity
criteria (version 2) grade 3 or greater treatment-related tox-
icity necessitating hospitalization.
Patients who had progressive disease and those who did not
undergo resection for other reasons are still analyzed in this report
on an intent-to-treat basis. Patients who did not proceed to oper-
ation because of early death, progression, or toxicity are still
included in the survival analysis. Statistical analysis for differences
in patient characteristics, resectability, pathologic staging, and
toxicity was performed with a 2-sided 2 test. Survival was esti-
mated actuarially by using Kaplan-Meier methods,11 and differ-
ences were assessed with the log-rank test. Statistical analysis was
performed by one of the co-authors (J.H.L.) with Stata software
(Stata Corp, College Station, Tex).
Results
A total of 53 patients were identified who satisfied the
inclusion criteria. Twenty-two (42%) received radiation
with EP chemotherapy, and the other 31 patients (58%)
received carboplatin/paclitaxel chemotherapy. Characteris-
tics of the patients are shown in Table 1. There were no
significant differences between the 2 treatment groups with
respect to age, stage of disease, sex, or radiation dose.
Patients who received EP chemotherapy presented with a
higher proportion of clinical T3/T4 disease and more favor-
able performance status. Median follow-up was 57 months
for all surviving patients, 65 months for patients who re-
ceived EP chemotherapy, and 46 months for patients who
received carboplatin/paclitaxel chemotherapy.
Resectability and Major Response Rate
After neoadjuvant therapy, operation was attempted for 45
(85%) of the 53 initial patients. Obvious distant metastases
developed in the other 8 patients, rendering operation inap-
propriate and thus making these patients inevaluable for
assessment of local response. Thirty-eight of the 45 patients
with operable disease had successful (R0) complete resec-
tion of all gross tumor, for an overall resectability rate in
this series of 72% (38/53). Three patients had an incomplete
resection (R1 or R2), and 4 patients were not operated on
because of a lack of clinical response to induction therapy or
death before surgery. A pathologic complete response was
identified in 7 patients (16% of operable patients, or 13% of
the entire patient population). Pathologic stage I to IIA
(T1-2 N0 M0 or T1 N1 M0) disease with marked his-
topathologic signs of a pathologic response to chemoradia-
tion was found in an additional 15 patients. Thus, a major
pathologic response occurred in 42% of the entire patient
population (49% of patients who underwent thoracotomy).
Survival
Median survival for all patients was 21 months. The 4- and
5-year actuarial survivals were 31% for the entire patient
population and 36% for the 45 patients who were consid-
ered operable and evaluable for response to neoadjuvant
therapy. Patients treated with EP/XRT had a 4-year actuarial
survival of 36%, compared with 26% for carboplatin/pacli-
taxel and XRT. This was not a statistically significant dif-
ference (P  .667). Initial performance status was also an
important factor, because 40% of patients without signifi-
cant cancer-related symptoms (performance status 0) were
long-term survivors, whereas none of the performance sta-
tus 1 patients survived beyond 3 years (P  .015).
Patients who achieved a major pathologic response as a
result of neoadjuvant therapy experienced more favorable
survival compared with those who had less than a major
response. The 4- and 5-year actuarial survival in the 22
patients with a major response was 48%, compared with
24% among the 23 operable patients who did not gain a
major response (P  .027). Survival at 4 years was 0% for
the 8 patients with progression. The survival curves based
on response are shown in Figure 1. A summary of treatment
outcomes is shown in Table 2.
Reanalysis of the survival data when excluding the 7
patients who did not have biopsy-proven N2 disease before
neoadjuvant therapy does not change the results. The asso-
ciation between major response and long-term survival re-
mains statistically significant (P  .05).
Patterns of Failure
A total of 12 patients had local-regional relapses or progres-
sion, including 3 patients who underwent successful oper-
ation but later experienced isolated supraclavicular nodal
TABLE 1. Patient characteristics
Characteristic
Entire
cohort
EP and XRT
group
Carboplatin/
paditaxel,
and XRT
group
n 53 22 31
Median age (y) 62 63 61
Male sex 29 (55%) 14 (64%) 15 (48%)
Clinical T3/T4 stage 23 (43%) 14 (62%) 9 (29%)
Squamous cell histology 10 (21%) 3 (14%) 7 (27%)
Significant weight
loss (5%)
7 (13%) 2 (9%) 5 (16%)
Performance status 0 39 (78%) 20 (91%) 19 (68%)
Median radiation dose
(Gy)
48 46 50
EP, Etoposide/cisplatin chemotherapy; XRT, radiotherapy.
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failure outside of the radiation fields. The crude local con-
trol rate for the entire population was thus 77% (83% local
control within the radiation field). For the 41 patients who
underwent operation, the crude local control rate (including
the supraclavicular recurrences as local failures) was 83%
(34/41). The local control rate within the surgical/radiother-
apeutic fields for these 41 patients was 90% (37/41). Among
the 12 patients who did not undergo thoracotomy, 5 expe-
rienced local-regional progression, all within 1 year after
XRT.
Brain metastases as the first site of failure occurred in 12
patients (23%). Brain metastases occurred in 8 patients who
underwent operation (8/41; 19.5%) and 4 patients who did
not undergo operation (4/12; 33%). This is not statistically
significant (P  .31). There were no statistically significant
differences in patterns of failure between EP/XRT and
carboplatin/paclitaxel and XRT as neoadjuvant therapy.
Morbidity and Mortality
One patient died after induction chemoradiotherapy (before
operation), and 2 patients died within 30 days after surgery,
all from respiratory failure. Two additional patients died of
respiratory disease between 30 and 90 days after surgery
without definite evidence of recurrent cancer. The relation-
ship between neoadjuvant therapy, operation, tumor, and
intercurrent disease with these early deaths is uncertain. The
overall rate of mortality potentially related to therapy in this
series was 5 (9%) of 53. Three of these 5 patients had
undergone right pneumonectomy. Early mortality occurred
in 3 of 7 patients who underwent right pneumonectomy in
this series. One of these deaths occurred 2 weeks after surgery
from complications after a pulmonary embolism; 1 death re-
sulted from a bronchopleural fistula and subsequent acute
respiratory distress syndrome 10 weeks after surgery; and 1
death occurred from pneumonia at 4 weeks after surgery.
Temporary and reversible severe (grade 3) gastrointesti-
nal toxicity (radiation esophagitis, nausea, or dehydration)
developed in 7 (13%) patients who underwent induction
TABLE 2. Outcome from treatment
Outcome
Entire
cohort
EP and XRT
group
Carboplatin/
paditaxel
and XRT
group
Severe acute toxicity 7/53 (13%) 6/22 (27%) 1/31 (3%)
Progressive disease 8/53 (15%) 2/22 (9%) 6/31 (19%)
Underwent resection 41/53 (77%) 19/22 (86%) 22/31 (71%)
Pathologic complete
response*
7/45 (16%) 3/20 (15%) 4/25 (16%)
Major response
(stage 0, I, or II)*
22/45 (49%) 11/20 (55%) 9/25 (44%)
Local-regional
control
41/53 (77%) 17/22 (77%) 24/31 (77%)
Distant metastasis 28/53 (53%) 13/22 (59%) 15/31 (48%)
5-y survival 31% 36% 26%
EP, Etoposide/cisplatin chemotherapy; XRT, radiotherapy.
*Proportion based on 45 patients without progressive disease during
neoadjuvant therapy.
Figure 1. Overall survival as a function of response to neoadjuvant chemoradiotherapy.
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chemoradiotherapy, necessitating treatment interruption
with or without a brief (1 week) hospitalization. This
occurred in 6 (27%) patients who received EP, compared
with 1 (3%) patient who received carboplatin/paclitaxel (P
 .02).
Discussion
Our study shows that the resectability rates and LRC for
stage IIIA NSCLC treated with neoadjuvant chemoradio-
therapy are high. The survival data in this series are similar
to phase II data reported by other studies of multimodality
therapy for clinical stage III NSCLC,5,8 as well as the
recently reported preliminary results of RTOG 93-09/INT
0139.4 It is disappointing that the overall survival and
relapse-free survival have not improved appreciably over
the past decade. This mainly reflects the inadequacy of
current therapies to sterilize micrometastatic disease, in-
cluding brain metastases.
This study included only patients with clinically obvious
stage IIIA and highly selected stage IIIB disease who were
not candidates for up-front operation. In this patient popu-
lation, it is extremely controversial whether to use bimodal-
ity nonsurgical therapy (chemoradiation), bimodality surgi-
cal therapy (chemotherapy followed by operation), or
trimodality therapy (chemoradiation followed by opera-
tion). RTOG 93-09/INT 0139 showed a progression-free
survival but not an overall survival advantage to trimodality
therapy compared with chemoradiation alone, and results
are not fully matured.4 There is no published randomized
trial comparing chemotherapy versus chemoradiotherapy as
induction therapy for stage IIIA NSCLC; 2 small trials
reported as meeting abstracts12,13 suggest better resectabil-
ity and LRC (but not overall survival) with neoadjuvant
chemoradiotherapy versus chemotherapy alone. The results
of the large US INT trial (chemoradiation vs chemoradia-
tion plus operation) and results from a large European trial
(chemotherapy/surgery vs chemoradiation/surgery) will be
extremely important. The US INT mechanism may open a
randomized trial of this design in the next year.
One argument against the routine use of XRT as part of
neoadjuvant regimens is that whereas published randomized
trials show an advantage of neoadjuvant chemotherapy plus
operation (with or without postoperative XRT) over opera-
tion alone (with or without postoperative XRT),14-16 there
has not been an analogous trial to confirm that neoadjuvant
chemoradiotherapy is superior to immediate operation.
However, the results of randomized studies on neoadjuvant
chemotherapy alone have been inconsistent. The 3 oft-
quoted trials referenced previously have very small sample
sizes, and the long-term follow-up data are less impressive
than the initial findings.17,18 A larger randomized study
from France showed no survival benefit to neoadjuvant
chemotherapy for stage IIIA NSCLC.19 These 3 studies may
have had a population of patients with less bulky, less
advanced disease than in our series or RTOG 93-09/INT
0139. A randomized study from the Lung Cancer Study
Group showed no advantage to preoperative chemotherapy
over preoperative XRT.20 A small randomized trial from the
National Cancer Institute of Canada showed no difference
between chemotherapy followed by operation versus XRT
alone for stage IIIA NSCLC.21 Again, it should be empha-
sized that the conflicting results from all of these trials may
indicate substantial differences in patient entry characteris-
tics, such as the extent of IIIA disease (minimal volume vs
bulky).
A second argument against the use of XRT as part of
neoadjuvant regimens is that it obfuscates the ability to use
pathologic response as a potential marker of long-term
prognosis. Our study suggests that pathologic response is a
useful predictor for long-term survival after chemoradia-
tion. Pathologic responders had improved LRC and overall
survival compared with nonresponders. Our data suggest
that pathologic response is probably a viable early surrogate
end point in future trials of marginally resectable NSCLC
treated with XRT as a component of neoadjuvant therapy.
Although achieving successful resection and LRC does
not guarantee long-term survival, it seems to be a necessary
component of treatment success. Only 1 of 12 patients who
did not undergo resection in our series was alive beyond 3
years of follow-up, and 5 patients had local-regional pro-
gression. Given the morbidity of local-regional failure, we
contend that LRC is an important end point to consider in
treatment decision-making for NSCLC.
Our study shows that serious toxicity was relatively high,
although acceptable. Treatment-related mortality was not
noticeably worse than with radical operation alone22 or
chemotherapy followed by operation.23 Because XRT doses
are limited to 45 to 54 Gy, the risk and duration of grade 3
esophagitis is lower than that with definitive chemoradiation
alone. Esophagitis seemed to be further reduced by the
switch from high-dose EP to carboplatin/paclitaxel, with no
loss of antitumor efficacy. It was disappointing to note that
the change from EP to carboplatin/paclitaxel did not mea-
surably improve outcomes; however, this is not surprising
in light of data from large stage IV NSCLC chemotherapy
studies.24
Our study is inherently limited by its retrospective, non-
randomized design and has potential for significant patient
selection bias. However, this study, although not random-
ized, does represent consecutive patients cared for by the
same team of oncologists according to preset institutional
treatment policies. As indicated by Table 1, the patient
population cannot be considered a favorable subgroup of
IIIA NSCLC. Until conclusive results from large random-
ized studies are available, institutional series such as ours
provide hypothesis-generating data that are relevant for
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future trial development and clinical practice. Future pro-
spective trials in our institution will build on a foundation of
neoadjuvant paclitaxel/carboplatin and XRT combinations
by judiciously adding targeted therapies.
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